SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL APPLICATION FOR NOVEL LY6G6D/4-1BB-TARGETING BISPECIFIC ANTIBODY HEC-921 INJECTION ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF THE PRC

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

On 18 June 2026, the Center for Drug Evaluation of the National Medical Products Administration of the PRC (the "**CDE**") officially accepted the clinical trial application submitted by the Group for its novel LY6G6D/4-1BB-targeting bispecific antibody HEC-921 injection. The Phase I clinical study is expected to officially commence in 2026.

I. INFORMATION ON THE ANTIBODY DRUG

HEC-921 is a self-developed bispecific antibody drug of the Company, which is intended to be used for the treatment of advanced solid tumors, with LY6G6D-positive colorectal cancer as its primary development direction. Through a design of tumor-targeting-dependent immune activation, HEC-921 utilizes the LY6G6D target to achieve tumor tissue-specific enrichment, while at the same time performing regional immune activation within the tumor microenvironment through the 4-1BB pathway to exert anti-tumor effects. To the best knowledge of the Company and based on publicly available information, as of the date of this announcement, there is no application for clinical trials for similar products either domestically or abroad.

As of the date of this announcement, HEC-921 has completed key research work required to support this clinical trial application, including Chemistry, Manufacturing, and Controls (CMC), pharmacology and efficacy, pharmacokinetics, and animal safety evaluation. Preclinical studies have shown that it exhibits excellent anti-tumor activity in multiple animal models, demonstrates synergistic effects when combined with anti-PD-1 antibodies and chemotherapy, and shows a good safety profile in cynomolgus monkeys.

II. SIGNIFICANCE OF THE PROJECT

Colorectal cancer is one of the malignant tumors with a high incidence globally, and there remain significant unmet clinical needs for patients with advanced stages. Leveraging its innovative LY6G6D/4-1BB bispecific antibody design, HEC-921 is expected to improve safety while enhancing efficacy, possessing important clinical development value.

The Group continues to focus on the research and development of innovative oncology drugs, making forward-looking layouts in the fields of immuno-oncology and precision therapy, and has successfully established a TCE technology platform with 4-1BB as its core. Currently, the clinical trial application for HEC-921, a project showing particularly rapid progress, has been accepted. In addition, relying on this technology platform, multiple preclinical pipelines simultaneously developed by the Group, such as the 4-1BB/CDH17 bispecific antibody, are also progressing smoothly as planned, and are expected to be successively filed to enter the clinical trial stage in the future.

Risk Warning: The research and development of new drugs is characterized by long cycles, high investment, and uncertainty. There is uncertainty in the subsequent clinical research and commercialization process of HEC-921, and investors are advised to pay attention to investment risks.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
18 June 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.